1AI Stock Overview
A pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Algorae Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.007 |
| 52 Week High | AU$0.013 |
| 52 Week Low | AU$0.005 |
| Beta | 0.72 |
| 11 Month Change | 16.67% |
| 3 Month Change | -22.22% |
| 1 Year Change | -41.67% |
| 33 Year Change | 0.014% |
| 5 Year Change | -63.16% |
| Change since IPO | -97.20% |
Recent News & Updates
Shareholder Returns
| 1AI | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | 1.5% |
| 1Y | -41.7% | 10.0% | 17.2% |
Return vs Industry: 1AI underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: 1AI underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| 1AI volatility | |
|---|---|
| 1AI Average Weekly Movement | 19.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: 1AI's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: 1AI's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | David Hainsworth | algoraepharma.com |
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company’s product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer’s disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient to treat cardiovascular disease, including hypertension. It is also developing AlgaraeOS in partnership with the University of New South Wales, an artificial intelligence platform for biopharmaceutical prediction of both fixed dose combination drug targets and repurposed drug targets agnostic to medical indication.
Algorae Pharmaceuticals Limited Fundamentals Summary
| 1AI fundamental statistics | |
|---|---|
| Market cap | AU$11.81m |
| Earnings (TTM) | -AU$2.10m |
| Revenue (TTM) | AU$125.20k |
94.3x
P/S Ratio-5.6x
P/E RatioIs 1AI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1AI income statement (TTM) | |
|---|---|
| Revenue | AU$125.20k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$125.20k |
| Other Expenses | AU$2.22m |
| Earnings | -AU$2.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0012 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,673.77% |
| Debt/Equity Ratio | 0% |
How did 1AI perform over the long term?
See historical performance and comparison